Literature DB >> 20662790

Metabolic profiling of bile in cholangiocarcinoma using in vitro magnetic resonance spectroscopy.

Amar W Sharif1, Horace R T Williams, Temi Lampejo, Shahid A Khan, Devinder S Bansi, David Westaby, Andrew V Thillainayagam, Howard C Thomas, I Jane Cox, Simon D Taylor-Robinson.   

Abstract

OBJECTIVES: Cholangiocarcinoma (CCA) has a poor prognosis and its aetiology is inadequately understood. Magnetic resonance spectroscopy (MRS) of bile may provide insights into the pathogenesis of CCA and help identify novel diagnostic biomarkers. The aim of this study was to compare the chemical composition of bile from patients with CCA with that of bile from patients with benign biliary disease.
METHODS: Magnetic resonance spectra were acquired from the bile of five CCA patients and compared with MRS of control bile from patients with benign biliary disease (seven with gallstones, eight with sphincter of Oddi dysfunction [SOD], five with primary sclerosing cholangitis [PSC]). Metabolic profiles were compared using both univariate and multivariate pattern-recognition analysis.
RESULTS: Univariate analysis showed that levels of glycine-conjugated bile acids were significantly increased in patients with CCA, compared with the benign disease groups (P= 0.002). 7 beta primary bile acids were significantly increased (P= 0.030) and biliary phosphatidylcholine (PtC) levels were reduced (P= 0.010) in bile from patients with CCA compared with bile from gallstone patients. These compounds were also of primary importance in the multivariate analysis: the cohorts were differentiated by partial least squares discriminant analysis (PLS-DA).
CONCLUSIONS: These preliminary data suggest that altered bile acid and PtC metabolism play an important role in CCA aetiopathogenesis and that specific metabolites may have potential as future biomarkers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20662790      PMCID: PMC3028580          DOI: 10.1111/j.1477-2574.2010.00185.x

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  28 in total

1.  Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998.

Authors:  S D Taylor-Robinson; M B Toledano; S Arora; T J Keegan; S Hargreaves; A Beck; S A Khan; P Elliott; H C Thomas
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

2.  Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics.

Authors:  Joanne T Brindle; Henrik Antti; Elaine Holmes; George Tranter; Jeremy K Nicholson; Hugh W L Bethell; Sarah Clarke; Peter M Schofield; Elaine McKilligin; David E Mosedale; David J Grainger
Journal:  Nat Med       Date:  2002-11-25       Impact factor: 53.440

3.  The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis.

Authors:  A H Patel; D M Harnois; G G Klee; N F LaRusso; G J Gores
Journal:  Am J Gastroenterol       Date:  2000-01       Impact factor: 10.864

4.  Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line.

Authors:  Jung-Hwan Yoon; Hajime Higuchi; Nathan W Werneburg; Scott H Kaufmann; Gregory J Gores
Journal:  Gastroenterology       Date:  2002-04       Impact factor: 22.682

5.  Nuclear magnetic resonance spectroscopy.

Authors:  I J Cox
Journal:  Br J Hosp Med       Date:  1988-09

Review 6.  The epidemiology of cholangiocarcinoma.

Authors:  Yasser Shaib; Hashem B El-Serag
Journal:  Semin Liver Dis       Date:  2004-05       Impact factor: 6.115

7.  Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis.

Authors:  T H Mauad; C M van Nieuwkerk; K P Dingemans; J J Smit; A H Schinkel; R G Notenboom; M A van den Bergh Weerman; R P Verkruisen; A K Groen; R P Oude Elferink
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

8.  Changing international trends in mortality rates for liver, biliary and pancreatic tumours.

Authors:  Shahid A Khan; Simon D Taylor-Robinson; Mireille B Toledano; Angus Beck; Paul Elliott; Howard C Thomas
Journal:  J Hepatol       Date:  2002-12       Impact factor: 25.083

9.  Detection and quantification of D-glucuronic acid in human bile using 1H NMR spectroscopy: relevance to the diagnosis of pancreatic cancer.

Authors:  Tedros Bezabeh; Omkar B Ijare; Nils Albiin; Urban Arnelo; Bo Lindberg; Ian C P Smith
Journal:  MAGMA       Date:  2009-04-24       Impact factor: 2.310

10.  Prospective, blinded assessment of factors influencing the accuracy of biliary cytology interpretation.

Authors:  Gavin C Harewood; Todd H Baron; Linda M Stadheim; Benjamin R Kipp; Thomas J Sebo; Diva R Salomao
Journal:  Am J Gastroenterol       Date:  2004-08       Impact factor: 10.864

View more
  21 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

Review 2.  Nuclear magnetic resonance based metabolomics and liver diseases: Recent advances and future clinical applications.

Authors:  Roland Amathieu; Mohamed Nawfal Triba; Corentine Goossens; Nadia Bouchemal; Pierre Nahon; Philippe Savarin; Laurence Le Moyec
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

3.  Differences in phosphatidylcholine and bile acids in bile from Egyptian and UK patients with and without cholangiocarcinoma.

Authors:  Mohamed S Hashim Abdalla; Simon D Taylor-Robinson; Amar W Sharif; Horace R T Williams; Mary M E Crossey; Gamal A Badra; Andrew V Thillainayagam; Devinder S Bansi; Howard C Thomas; Imam A Waked; Shahid A Khan
Journal:  HPB (Oxford)       Date:  2011-03-22       Impact factor: 3.647

4.  Nuclear magnetic resonance metabolomics and human liver diseases: The principles and evidence associated with protein and carbohydrate metabolism.

Authors:  Laurence Le Moyec; Mohamed N Triba; Pierre Nahon; Nadia Bouchemal; Edith Hantz; Corentine Goossens; Roland Amathieu; Philippe Savarin
Journal:  Biomed Rep       Date:  2017-03-03

5.  Bile Processing Protocol for Improved Proteomic Analysis.

Authors:  Sergio Ciordia; Gloria Alvarez-Sola; María Rullán; Jesús M Urman; Matías A Ávila; Fernando J Corrales
Journal:  Methods Mol Biol       Date:  2022

Review 6.  The metabolomic window into hepatobiliary disease.

Authors:  Diren Beyoğlu; Jeffrey R Idle
Journal:  J Hepatol       Date:  2013-05-25       Impact factor: 25.083

7.  Non-invasive fecal metabonomic detection of colorectal cancer.

Authors:  Lee Cheng Phua; Xiu Ping Chue; Poh Koon Koh; Peh Yean Cheah; Han Kiat Ho; Eric Chun Yong Chan
Journal:  Cancer Biol Ther       Date:  2014-01-14       Impact factor: 4.742

Review 8.  Current and future roles of mucins in cholangiocarcinoma-recent evidences for a possible interplay with bile acids.

Authors:  Elisa Danese; Andrea Ruzzenente; Martina Montagnana; Patricia Marie-Jeanne Lievens
Journal:  Ann Transl Med       Date:  2018-09

9.  Characterisation of the Serum Metabolic Signature of Cholangiocarcinoma in a United Kingdom Cohort.

Authors:  Munirah Alsaleh; Zoe Leftley; Thomas A Barbera; Larry K Koomson; Abigail Zabron; Mary M E Crossey; Helen L Reeves; Matthew Cramp; Stephen Ryder; Shaun Greer; Martin Prince; Paiboon Sithithaworn; Mohamed Shariff; Narong Khuntikeo; Watcharin Loilome; Puangrat Yongvanit; Yi-Liang Shen; I Jane Cox; Roger Williams; Christopher A Wadsworth; Elaine Holmes; Kathryn Nash; Simon D Taylor-Robinson
Journal:  J Clin Exp Hepatol       Date:  2019-06-15

10.  Metabolic Profiling of Praziquantel-mediated Prevention of Opisthorchis viverrini-induced Cholangiocyte Transformation in the Hamster Model of Cholangiocarcinoma.

Authors:  Pattama Prommajun; Jutarop Phetcharaburanin; Nisana Namwat; Poramate Klanrit; Prakasit Sa-Ngiamwibool; Malinee Thanee; Hasaya Dokduang; Yingpinyapat Kittirat; Jia V Li; Watcharin Loilome
Journal:  Cancer Genomics Proteomics       Date:  2021 Jan-Feb       Impact factor: 4.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.